Add To Watchlist
Share URL
About The Company
CEO
Dr. Geraldine A. Henwood
Market Cap
4.42 Million USD
Sector
Healthcare
Website
https://www.baudaxbio.comDescription
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings.
Read More
Overview
Value
1
Growth
66
Health
23
Management
60
Analyst Opinion
63
Total
43
All Scores Out Of 100
Best Features
- Very strong cashflow and earnings growth
- Earnings growth has improved recently
- Has a low level of debt
- Low preportion of income is paid as dividend
Risk Factors
- Overvalued on cashflow basis
- Income is not covering expenditure and investment
- Earnings are negative
- There is a history of diluting shareholders 0
- Poor overall financial health
- No margin of safety at their current market price 0
Latest News

Is the Pain Over for Baudax Bio Investors after a 70% Spike?
MarketBeat | 09:01 Thu 26 Jan 2023
Read More →

Why Is Baudax Bio (BXRX) Stock Up 50% Today?
InvestorPlace | 15:58 Tue 24 Jan 2023
Read More →

Penny Stocks Risk Management: 3 Tips and Tricks
PennyStocks | 11:00 Fri 30 Dec 2022
Read More →

The 7 Most Sold-Off Stocks of 2022
InvestorPlace | 21:27 Sat 24 Dec 2022
Read More →
Market Peers
BXRX
Key Figures
PE Ratio (TTM)
N/A
Margin Of Safety (DCF)
-5573.55%
Revenue Growth (5 Year Average)
12.36%
Ratings Consensus
Neutral
Share Buybacks
-28.71%
Dividend Yeild (TTM)
N/A
Valuation
Value Score
1
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: N/A✘
Current Price: 1.7 USD
Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
N/Ax
Free Cashflow Yeild
-1103.94%
PE/Earnings Growth
N/A
Price/Book
-0.18x
Growth
Growth Score
66
- ✔ 5 Year Average Revenue growth of 12.36% is higher than the market average (10.97%)
- ✔ Revenue growth has improved this yeara
- ✔ 5 Year Average Earnings growth of 23.98% is higher than the market average (14.48%)
- ✔ Earnings growth has improved this year
- ✔ 5 Year Average Cashflow growth of 15.17% is higher than the market average (12.35%)
- ✘ Free Cashflow growth has slowed this year
Revenue Growth
12.36%
Earnings Growth
23.98%
Cashflow Growth
15.17%
Health
Health Score
23
Altman Z Score
N/A
Piostroski Score
3.00
Debt/Equity
0.65x
Current Assets/Liabilities
1.50x
Free Cashflow/Total Debt
N/Ax
Debt/Capital
0.36x
Management
Management Score
60
Average Buybacks/Dilution
-28.71%
Recent Buybacks/Dilution
N/A
5 Year Price Volitility
90.21%
Return On Assets
-11103599.32%
Return On Capital Employed
-31.33%
Return On Equity
-44727541.28%
Return On Free Cashflow
13235037.27%
Return On Investments
N/A
Analysts
Analyst Opinion
63
- ✔ Ratings consensus is Neutral
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Baudax Bio, Inc.
Currency
USD
Beta
1.579706
Vol Avg
1313411
Ceo
Dr. Geraldine A. Henwood
Cik
0001780097
Cusip
07160F206
Exchange
NASDAQ Capital Market
Full Time Employees
80
Industry
Biotechnology
Sector
Healthcare
Ipo Date
2019-11-14
Address
490 Lapp Rd
City
Malvern
State
PENNSYLVANIA
Country
US
Zip
19355
Phone
14843952470
All financial data provided by FMP